Pfizer and valneva issue update on phase 3 clinical trial evaluating lyme disease vaccine candidate vla15

New york & saint- herblain (france), february 17, 2023 – pfizer inc. (nyse: pfe) and valneva se (nasdaq: valn; euronext paris: vla) today announce that pfizer, as the study sponsor, has decided to discontinue a significant percentage of participants in the u.s. who had been enrolled in the vaccine against lyme for outdoor recreationists (valor) (nct05477524) phase 3 clinical study. the study is investigating the efficacy, safety and immunogenicity of an investigational lyme disease vaccine candidate, vla15. these study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of good clinical practice (gcp) at certain clinical trial sites run by a third-party clinical trial site operator. the discontinuation of these participants was not due to any safety concerns with the investigational vaccine and was not prompted by a participant-reported adverse event.
VALN Ratings Summary
VALN Quant Ranking